October 24, 2025
ToxoTech joins the Nordic Mentor Network for Entrepreneurship (NOME)

ToxoTech has been accepted into the Nordic Mentor Network for Entrepreneurship (NOME), a leading mentorship programme supporting high-potential life science startups across the Nordic region. Through NOME, we will receive tailored guidance from experienced industry mentors to help refine our strategy and support the continued development of our next-generation botulinum neurotoxin therapeutics.

We look forward to engaging with the NOME community and benefiting from its strong network of expertise and collaboration.

More information about the NOME programme is available at: https://nome.nu/

Latest
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
News
From toxins to therapies
Stockholm University researchers redesign botox
Read article
Publications
New study reveals BoNT/A mutants with enhanced ganglioside binding and increased potency
Our collaborative research identifies BoNT/A variants with improved ganglioside engagement, providing insights into how receptor interactions shape potency and selectivity.
Read article
Latest
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Events
ToxoTech founders to present at INA Toxins 2026 in Madrid
Geoffrey Masuyer and Pål Stenmark will share recent research findings at the upcoming INA Toxins conference, a key international meeting for the botulinum neurotoxin field.
News
ToxoTech and AAX Biotech and Join Forces to Advance Next-Generation Biotherapeutics
ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, and AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, today announced a strategic collaboration to advance next-generation biotherapeutics.
ToxoTech joins the Nordic Mentor Network for Entrepreneurship (NOME)
ToxoTech will receive tailored mentorship through the NOME programme to support strategic development and company growth.
News
From toxins to therapies
Stockholm University researchers redesign botox
Publications
New study reveals BoNT/A mutants with enhanced ganglioside binding and increased potency
Our collaborative research identifies BoNT/A variants with improved ganglioside engagement, providing insights into how receptor interactions shape potency and selectivity.
This component will only work on the published/exported site. Full documentation in Finsweet's Attributes docs.